Yanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction and esophageal cancers.
Yanghee Woo, MD, surgical oncologist in the Division of Surgical Oncology, associate professor in the Department of Surgery, vice chair of international affairs, director of the Gastroenterology and Minimally Invasive Therapies Program at City of Hope, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction (GEJ) and esophageal cancers.
Transcription:0:09 | The CROSS trial included patients, not just with adenocarcinoma, but with squamous cell carcinoma as well. Overall, their survival benefit for adenocarcinoma was an overall median survival of 43 months vs 27 months. Unfortunately, it was very close to being statistically significant, but it was not as significant as for those patients who had squamous cell adenocarcinoma of the esophagus. There was a marked improvement in patients with squamous cell.
0:50 | The 16-month overall survival benefit is real, so despite the nonsignificance, this became standard of care. The study did include 76% of patients with esophageal and only 24% of patients with GEJ tumors, so we need to consider these things when we are sort of evaluating the clinical trial results.
1:18 | In terms of overall survival rates, CROSS did a good job with chemoradiation therapy before surgery for our patients vs surgery alone. Additionally in the Journal of Clinical Oncology in 2021, this concern about the overall survival benefit of the CROSS regiment was brought up. The 10-year overall survival benefit for CROSS persisted, and we saw that 38% of the patients who received neoadjuvant therapy plus surgery vs surgery alone remained alive. [For] surgery alone, only 25% of the patients were alive in 10 years after their surgery, but with the chemo XRT, 38 patients were alive.
2:24 | In this 10-year overall survival benefit, which means that 68% to 75% of these patients had died, and what was notable was that comparing the 2 regimens showed no improvement in isolated distant recurrence control, meaning that with chemo XRT, we fail to control this recurrences or metastases compared with surgery alone. That goes to highlight the strength of the neoadjuvant chemo XRT improving the real R0 rate for surgical resection.
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Phase 1b/2 Study of BXQ-350 in Metastatic Colorectal Cancer Completes Enrollment
November 27th 2024Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.
Read More